| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9940688 | American Journal of Hypertension | 2005 | 7 Pages |
Abstract
The superior BP-lowering potency of the fixed combination irbesartan/HCTZ (150/12.5 mg) over valsartan/HCTZ (80/12.5 mg), evidenced independently from the investigators by HBPM, supports the use of this technique in trials with prospective, randomized, open-label, blinded-endpoint designs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Guillaume Bobrie, Jean Delonca, Cyril Moulin, Alain Giacomino, Nicolas Postel-Vinay, Roland Asmar,